PMID- 16371717
OWN - NLM
STAT- MEDLINE
DCOM- 20060314
LR  - 20201209
IS  - 1598-9992 (Print)
IS  - 1598-9992 (Linking)
VI  - 46
IP  - 6
DP  - 2005 Dec
TI  - [Comparison of Helicobacter pylori eradication rate according to different 
      PPI-based triple therapy--omeprazole, rabeprazole, esomeprazole and 
      lansoprazole--].
PG  - 433-9
AB  - BACKGROUND/AIMS: Helicobacter pylori (H. pylori) is an important cause of various 
      gastrointestinal diseases. H. pylori eradication is essential for the cure and 
      prevention of associated diseases. Nowdays, proton pump inhibitor (PPI)-based 
      triple therapy is the standard eradication regimen. The aims of this study were 
      to compare the H. pylori eradication rate of different PPI-based triple therapies 
      and to find out the factors influencing the eradication rate. METHODS: From May 
      2002 through February 2004, H. pylori infected patients were treated with the 
      eradication regimen based on one of the four PPIs (omeprazole, rabeprazole, 
      esomeprazole and lansoprazole) for 1 or 2 weeks. After two weeks, drug 
      compliance, adverse effects, and smoking history during the eradication therapy 
      were obtained. The follow-up H. pylori test was performed 4 weeks after the 
      completion of therapy. The data were analyzed by Chi-square test and multiple 
      logistic regression analysis. RESULTS: Overall eradication rate was 83.5%. There 
      was no significant difference in eradication rate among four PPIs (p=0.379). Odds 
      ratio (OR) for omeprazole and rabeprazole was 1.15 (95% CI 0.50-2.68); for 
      omeprazole and esomeprazole, OR 1.63 (95% CI 0.68-3.89); and for omeprazole and 
      lansoprazole, OR 1.13 (95% CI 0.50-2.56). Smoking habit, site of ulcer, and the 
      duration of therapy affected the eradication rate significantly. CONCLUSIONS: The 
      efficacy of four different PPIs for H. pylori eradication is similar to each 
      other. Smoking, site of ulcer, and the duration of treatment have significant 
      effects on eradication rates.
FAU - Keum, Bora
AU  - Keum B
AD  - Department of Internal Medicine, Institute of Digestive Diseases and Nutrition, 
      Korea University College of Medicine, Seoul, Korea.
FAU - Lee, Sang Woo
AU  - Lee SW
FAU - Kim, Se Yune
AU  - Kim SY
FAU - Kim, Jeong Min
AU  - Kim JM
FAU - Choung, Rok Son
AU  - Choung RS
FAU - Yim, Hyung Joon
AU  - Yim HJ
FAU - Jeen, Yoon Tae
AU  - Jeen YT
FAU - Lee, Hong Sik
AU  - Lee HS
FAU - Chun, Hoon Jai
AU  - Chun HJ
FAU - Um, Soon Ho
AU  - Um SH
FAU - Choi, Jai Hyun
AU  - Choi JH
FAU - Kim, Chang Duck
AU  - Kim CD
FAU - Ryu, Ho Sang
AU  - Ryu HS
FAU - Hyun, Jin Hai
AU  - Hyun JH
LA  - kor
PT  - Comparative Study
PT  - Journal Article
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Anti-Infective Agents/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - *Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Proton Pump Inhibitors
EDAT- 2005/12/24 09:00
MHDA- 2006/03/15 09:00
CRDT- 2005/12/24 09:00
PHST- 2005/12/24 09:00 [pubmed]
PHST- 2006/03/15 09:00 [medline]
PHST- 2005/12/24 09:00 [entrez]
AID - 200512253 [pii]
PST - ppublish
SO  - Korean J Gastroenterol. 2005 Dec;46(6):433-9.